• Explore /
  • Poster
  • / Application of the albumin-bilirubin (ALBI) grade as predictive marker of atezolizumab plus bevacizumab (A+B) treatment outcomes for patients with advanced hepatocellular carcinoma (HCC): Real-world retrospective analysis at Veterans Health Administration (VHA).

Application of the albumin-bilirubin (ALBI) grade as predictive marker of atezolizumab plus bevacizumab (A+B) treatment outcomes for patients with advanced hepatocellular carcinoma (HCC): Real-world retrospective analysis at Veterans Health Administration (VHA).

Abstract Poster

Authors

null

Munaf Alkadimi

University of Texas Health Science Center at San Antonio, San Anonio, TX

Munaf Alkadimi , Maria Elena Fierro , Lauren Diaz Boyle , Kana Lucero , Kathleen Franklin , Michael Mader , Zohra Nooruddin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer - Advanced/Metastatic Disease

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4107)

DOI

10.1200/JCO.2023.41.16_suppl.4107

Abstract #

4107

Poster Bd #

428

Abstract Disclosures

Similar Posters

First Author: Timothy J. Brown

First Author: Jay Parekh

First Author: Munaf Alkadimi

First Author: Hirokazu Takahashi